Core Viewpoint - A class action securities lawsuit has been filed against Sana Biotechnology, Inc. due to alleged securities fraud affecting investors between March 17, 2023, and November 4, 2024 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [2]. - It is alleged that product candidates SC291 in oncology, SC379, and SG299 were less promising than previously communicated to investors [2]. - To preserve cash and focus on more promising candidates, Sana is likely to decrease funding for SC291, SC379, and SG299, and significantly reduce its workforce [2]. - The defendants are accused of overstating Sana's financial capacity to maintain operations and advance product candidates, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant timeframe have until May 20, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the U.S. [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sana Biotechnology, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Sana securities between March 17, 2023, and November 4, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 20, 2025 [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Sana made false and misleading statements regarding its financial health and the potential of its product candidates [4]. - Specific claims include that Sana was at significant risk of insufficient funds to maintain operations and that certain product candidates were less promising than represented [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sana Biotechnology, Inc. regarding a class action lawsuit due to allegations of materially false and misleading statements made by the company during a specified class period [1][2]. Group 1: Allegations Against Sana Biotechnology - The complaint alleges that during the class period from March 17, 2023, to November 4, 2024, Sana was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [1]. - It is claimed that product candidates SC291 in oncology, SC379, and SG299 were less promising than what the defendants had communicated to investors [1]. - To preserve cash and focus on more promising candidates, Sana was likely to decrease funding for or discontinue SC291, SC379, and SG299, as well as significantly reduce its workforce [1]. - The defendants allegedly overstated Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [1]. Group 2: Class Action Participation - Shareholders who purchased shares of SANA during the class period are encouraged to register for the class action, with a deadline of May 20, 2025, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: About The Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sana Biotechnology, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on May 20, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Sana securities between March 17, 2023, and November 4, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 20, 2025 [2][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3]. - The firm has been recognized for its achievements, including the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Sana made false or misleading statements regarding its financial stability and the potential of its product candidates, including SC291, SC379, and SG299 [4]. - It is claimed that Sana was at significant risk of insufficient funds to maintain operations and that the company was likely to reduce funding for certain product candidates and significantly cut its workforce [4].

Core Viewpoint - A class action securities lawsuit has been filed against Sana Biotechnology, Inc. due to alleged securities fraud affecting investors between March 17, 2023, and November 4, 2024 [1][2]. Group 1: Allegations and Financial Concerns - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [2]. - It is alleged that the product candidates SC291 in oncology, SC379, and SG299 were less promising than previously communicated to investors [2]. - To preserve cash and focus on more promising candidates, Sana was likely to decrease funding for or discontinue SC291, SC379, and SG299, as well as significantly reduce its workforce [2]. - The defendants are accused of overstating Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant timeframe have until May 20, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sana Biotechnology, Inc. regarding a class action lawsuit due to allegations of misleading statements and financial misrepresentation during a specified class period [1][3]. Group 1: Allegations Against Sana Biotechnology - The complaint alleges that during the class period from March 17, 2023, to November 4, 2024, Sana was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [3]. - It is claimed that product candidates SC291 in oncology, SC379, and SG299 were less promising than what the defendants had communicated to investors [3]. - To preserve cash and focus on more promising candidates, Sana was likely to decrease funding for or discontinue SC291, SC379, and SG299, as well as significantly reduce its workforce [3]. - The defendants allegedly overstated Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [3]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is May 20, 2025, and there is no cost or obligation to participate [4]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [4]. - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and fraud, emphasizing the importance of responsible business practices [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sana Biotechnology, Inc. regarding a class action lawsuit due to allegations of misleading statements and financial misrepresentation during a specified class period [1][2]. Group 1: Allegations Against Sana Biotechnology - The complaint alleges that Sana was at significant risk of having insufficient funds to maintain its current operations and advance its product candidates [1]. - It is claimed that product candidates SC291 in oncology, SC379, and SG299 were less promising than previously communicated to investors [1]. - To preserve cash and focus on more promising candidates, Sana is likely to decrease funding for SC291, SC379, and SG299, and significantly reduce its workforce [1]. - The defendants allegedly overstated Sana's financial capacity to maintain operations and advance existing product candidates [1]. - As a result, the public statements made by the defendants were materially false and/or misleading throughout the relevant period [1]. Group 2: Class Action Participation - Shareholders who purchased shares of SANA during the class period from March 17, 2023, to November 4, 2024, are encouraged to register for the class action [2]. - The deadline for shareholders to seek lead plaintiff status is May 20, 2025, and there is no cost or obligation to participate [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Group 3: About The Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Summary of Sana Biotechnology Conference Call Company Overview - **Company**: Sana Biotechnology (SANA) - **Event**: 2025 Bank of America Healthcare Conference - **Date**: May 13, 2025 Key Points on Type One Diabetes - **Disease Impact**: Type one diabetes affects approximately nine million people globally, leading to a reduced lifespan of 10-15 years and significant daily challenges for patients [4][5] - **Unmet Medical Need**: No new drug has been developed for type one diabetes since insulin in 1923, indicating a substantial unmet need for better treatment options [5] - **Current Research**: Sana is focusing on gene-modified pluripotent stem cells to create a scalable source of pancreatic islets for transplantation, aiming to eliminate the need for immunosuppression [10][12] Recent Data and Developments - **Clinical Data**: A patient treated with gene-modified islet cells has been insulin-free for over 30 years, with no signs of immunologic response after 12 weeks [10][12] - **Future Plans**: An Investigational New Drug (IND) application is anticipated next year, with the goal of beginning human treatments [11][12] Challenges and Considerations - **Scaling Production**: Significant work is required to scale the production of gene-modified islets to meet the needs of the nine million affected individuals [18][20] - **Manufacturing Process**: The manufacturing process must be locked in before starting pivotal studies, which is expected to take about a year [29] Other Pipeline Assets - **CAR T Cell Therapy**: Sana is applying hypoimmune technology to develop allogeneic CAR T cells, addressing challenges in the autoimmune setting and aiming for improved patient convenience [31][32] - **Ongoing Studies**: Two studies, Gleam and Vivid, are ongoing, with data expected later this year [30] Market and Financial Considerations - **Investment Landscape**: The company acknowledges the need for increased investment to continue development, particularly in the competitive field of cell and gene therapy [39][40] - **Return on Investment**: The potential for high ROI is emphasized, contingent on successful scaling and safety of the diabetes treatment [43][44] Regulatory Environment - **FDA Interactions**: The company is optimistic about upcoming meetings with the FDA to confirm testing protocols for their gene-modified therapies [17] Conclusion - **Commitment to Diabetes Asset**: Sana Biotechnology is committed to advancing its diabetes treatment while navigating the complexities of scaling production and ensuring safety [42]

Core Viewpoint - A class action securities lawsuit has been filed against Sana Biotechnology, Inc. due to alleged securities fraud affecting investors between March 17, 2023, and November 4, 2024 [1][2]. Group 1: Allegations and Financial Concerns - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [2]. - It is alleged that product candidates SC291 in oncology, SC379, and SG299 were less promising than previously communicated to investors [2]. - To preserve cash and focus on more promising candidates, Sana is likely to decrease funding for or discontinue SC291, SC379, and SG299, as well as significantly reduce its workforce [2]. - The defendants are accused of overstating Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant timeframe have until May 20, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities 2025 Healthcare Conference at 9:20 a.m. PT on Tuesday, May 13, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sana’s website ...